Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

NCT06196255 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: anti-FcRL5 CAR-T

Sponsor

Xuzhou Medical University